Autolus Therapeutics (AUTL) Q2 2024 earnings summary

Executive summary

• Obe-cel regulatory review ongoing in the US, UK, and EU, with FDA PDUFA target date of November 16, 2024; EMA and MHRA submissions accepted.

• FELIX Phase 2 data show 78% CR/CRi rate in r/r adult B-ALL, with 40% of responders in ongoing remission without SCT at median 21.5 months follow-up.

• SLE Phase 1 CARLYSLE study dosed first patient in Q2 2024; initial data expected late 2024.

• Board and leadership team expanded, including new chair and director, to support commercialization and pipeline growth.

• Major agreements with BioNTech and Cardinal Health to enhance clinical, commercial, and distribution capabilities.

Financial highlights

• Cash and cash equivalents at June 30, 2024: $705.9 million, up from $239.6 million at end of 2023.

• Q2 2024 net loss: $58.3 million, compared to $45.6 million in Q2 2023; six-month net loss of $111.0 million.

• Q2 2024 operating expenses: $58.9 million, up from $44.4 million in Q2 2023, driven by higher R&D and G&A costs.

• License revenue for Q2 2024 was $10.1 million, up from $1.3 million in Q2 2023, mainly from BioNTech agreement.

• Interest income increased to $9.7 million in Q2 2024; interest expense for H1 2024 was $29.4 million.

Outlook and guidance

• Sufficient cash runway to support obe-cel launch, commercialization, and pipeline development for at least 12 months.

• FDA decision expected November 2024; first US patient dosing likely in early 2025.

• Initial SLE Phase 1 data and further FELIX updates expected late 2024.

• Expenses anticipated to rise with pre-commercial readiness, manufacturing, and clinical development.

• Focus on regulatory approval, launch execution, and advancing next pivotal study.